Artiva Biotherapeutics (NASDAQ:ARTV) Stock Gets Downgrade from Wall Street Zen

Artiva Biotherapeutics (NASDAQ:ARTV - Get Free Report) was downgraded by research analysts at Wall Street Zen from a "sell" rating to a "strong sell" rating in a research report issued to clients and investors on Saturday, Wall Street Zen reports.

A number of other brokerages also recently issued reports on ARTV. Cantor Fitzgerald reaffirmed an "overweight" rating and set a $40.00 price target on shares of Artiva Biotherapeutics in a research report on Friday, October 2nd. HC Wainwright reissued a "buy" rating on shares of Artiva Biotherapeutics in a research report on Friday, October 2nd. TD Cowen cut Artiva Biotherapeutics from a "buy" rating to a "hold" rating in a research report on Tuesday, October 27th. Wedbush downgraded Artiva Biotherapeutics from an "outperform" rating to a "neutral" rating and set a $4.00 target price on the stock. in a research note on Tuesday, October 27th. Finally, Jefferies Financial Group lowered Artiva Biotherapeutics from a "buy" rating to a "hold" rating and set a $4.00 target price on the stock. in a research report on Thursday, October 29th. Two equities research analysts have rated the stock with a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat.com, Artiva Biotherapeutics currently has a consensus rating of "Hold" and a consensus price target of $24.80.

Artiva Biotherapeutics Stock Performance

NASDAQ:ARTV opened at $4.01 on Friday. Artiva Biotherapeutics has a fifty-two week low of $2.96 and a fifty-two week high of $14.53. The company's 50-day simple moving average is $6.66 and its 200-day simple moving average is $7.93.

Artiva Biotherapeutics (NASDAQ:ARTV - Get Free Report) last posted its quarterly earnings data on Monday, November 9th. The company reported ($0.56) EPS for the quarter, missing the consensus estimate of ($0.55) by ($0.01). On average, sell-side analysts predict that Artiva Biotherapeutics will post -2.74 earnings per share for the current fiscal year.

Insider Activity at Artiva Biotherapeutics

In other news, CEO Fred Aslan sold 61,696 shares of the business's stock in a transaction on Monday, October 5th. The shares were sold at an average price of $6.84, for a total transaction of $422,000.64. Following the sale, the chief executive officer directly owned 1,543,069 shares of the company's stock, valued at $10,554,591.96. The trade was a 3.84% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, COO Jennifer Bush sold 8,370 shares of the company's stock in a transaction on Monday, October 5th. The shares were sold at an average price of $6.84, for a total value of $57,250.80. Following the completion of the transaction, the chief operating officer directly owned 366,159 shares in the company, valued at approximately $2,504,527.56. The trade was a 2.23% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last three months, insiders sold 137,048 shares of company stock worth $1,086,167. Corporate insiders own 1.80% of the company's stock.

Institutional Investors Weigh In On Artiva Biotherapeutics

A number of large investors have recently bought and sold shares of ARTV. 5AM Venture Management LLC purchased a new stake in shares of Artiva Biotherapeutics in the 2nd quarter valued at $22,827,049. Blue Owl Capital Holdings LP acquired a new stake in shares of Artiva Biotherapeutics in the second quarter worth $8,483,000. BlackRock Inc. acquired a new stake in shares of Artiva Biotherapeutics in the second quarter worth $6,739,000. Nantahala Capital Management LLC acquired a new stake in shares of Artiva Biotherapeutics in the second quarter worth $2,910,000. Finally, Alyeska Investment Group L.P. raised its holdings in shares of Artiva Biotherapeutics by 173.6% during the second quarter. Alyeska Investment Group L.P. now owns 273,615 shares of the company's stock worth $2,654,000 after purchasing an additional 173,615 shares during the last quarter.

Artiva Biotherapeutics Company Profile

Artiva Biotherapeutics is a San Diego-based clinical-stage biotechnology company developing allogeneic, or donor-derived, natural killer (NK) cell therapies. Its approach is designed to provide ready-made cell treatments for patients with cancer and autoimmune diseases. The company's lead candidate, AlloNK (also known as AB-101), is an investigational NK cell therapy being studied in combination with antibody treatments. Artiva is evaluating its potential in autoimmune conditions and in cancers, including B-cell malignancies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.